Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
Four of the five cancer assets have been discontinued entirely, and the company is currently determining next steps for the arthritis candidate.
Darren Incorvaia
May 7, 2026 11:15am
Blackstone Invests $250M in Anagram to reduce CF pill burden
May 7, 2026 10:36am
Scaling theranostics through access, safety and trust
Brought to you by
Curium
Ascendis axes IL-2 program in retreat from oncology expansion
May 7, 2026 10:10am
Carl Sailer on AI, market trends, and strategic planning in biotech
Brought to you by
Syneos Health
Roche shells out up to $1B for PathAI to boost AI diagnostics
May 7, 2026 9:30am
